ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "PharmAthene, Inc." (PIP) Report Updated: Aug 22, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"PharmAthene, Inc." (PIP)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: MNOV,SPHS,DMPI,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"PharmAthene, Inc."© quotemedia

Company Profile

PharmAthene, Inc., a biodefense company, develops and commercializes medical counter measures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the Biomedical Advanced Research and Development Authority, Chemical Biological Medical Systems, and the National Institute of Allergy and Infectious Diseases. It has collaboration with Bristol-Myers Squibb for developing Valortim; and strategic alliance with Nanotherapeutics, Inc. to develop biodefense programs. The company is headquartered in Annapolis, Maryland.